nikiford564875

nikiford564875

2 Followers · 3 Following

No tracks found

Info

0 Tracks
Male
Social Links
Bio
We do not endorse non-Cleveland Clinic products or services. Cleveland Clinic is a non-profit academic medical center. Although homologous to the male prostate (developed from the same embryological tissues), various aspects of its development in relation to the male prostate are widely unknown and a matter of research.
The prostate is the only male accessory gland that occurs in cetaceans, consisting of diffuse urethral glands surrounded by a very powerful compressor muscle. In some marsupial species, the size of the prostate gland changes seasonally. The structure of the prostate varies, ranging from tubuloalveolar (as in humans) to branched tubular. The presence of a functional prostate in monotremes is controversial, and if monotremes do possess functional prostates, they may not make the same contribution to semen as in other mammals.
We measured the serum testosterone level in the patients only once, before their biopsy was done. Patients without prostate cancer had relatively lower PSA and larger prostates than did patients with prostate cancer. Ideas about the interaction between testosterone and prostate cancer have changed considerably over the past decade. In 1995 Wu et al found that the distribution of dihydrotestosterone-to-testosterone ratios parallels both the incidence of and mortality from prostate cancer . Recent chemopreventive trials with 5-alpha-reductase inhibitors show the role of testosterone in prostate cancer development .
There is no specific normal or abnormal serum level of PSA though most doctors considered PSA levels of 4.0 ng ml−1 and lower to be within the normal range. Prostate-specific antigen (PSA) is a glycoprotein produced almost exclusively by prostate epithelial cells, which have androgen receptor (AR). However, more studies have shown that around 15% of men with low or normal PSA levels have PCa. Prostate-specific antigen (PSA) testing has been widely used to screen men for prostate cancer (PCa) and to monitor PCa progression. In other included studies, Bauman et al19 reported that transdermal testosterone improved lean tissue mass in men with spinal cord injuries, and Merza et al26 found that transdermal testosterone increased lean body mass and decreased bone absorption in men with borderline hypogonadism. In one of the larger studies included in the current analysis, Legros et al24 examined the effect of oral testosterone undecanoate in men with symptomatic hypogonadism in a multicenter, randomized, double-blind, placebo-controlled trial and found that testosterone replacement did not improve the total Aging Males’ Symptom score after 6 months of treatment, except in the sexual symptom subdomain were a modest improvement seen with a dose of 160 mg/day.
An infection or inflammation of the prostate or having had a recent prostate biopsy can cause PSA levels to be raised for a month or two. Thus, if the initial PSA reading is about 10 ng/mL and it rises rapidly year on year, this can point to early-stage prostate cancer. The amount by which the prostate-specific antigen (PSA) levels rise in a year is called PSA velocity.
A few studies published during the past decade contrast with our results, however, and show that low testosterone levels seem to be related to an increased risk of prostate cancer and tumor aggressiveness, such as a high Gleason score 23-28. As PSA is a primary screening tool for prostate cancer, and testosterone replacement therapy is being widely used for the treatment of age-related male hypogonadism, the purpose of this systematic review and meta-analysis was to determine the effect of testosterone replacement therapy on PSA levels in men being treated for hypogonadism. We found that the serum testosterone level at the time of diagnosis was unrelated to PSA and prostate cancer risk and aggressiveness in both hypogonadal and eugonadal patients. However, a recent study refuted any connection between elevated testosterone levels and increased prostate cancer risk 10,21. In the 1960s, large studies showed estrogen therapy to be as effective as surgical castration at treating prostate cancer, but that those on estrogen therapy were at increased risk of suffering blood clots. In 1941, Charles Huggins and Clarence V. Hodges published two studies using surgical castration or oral estrogen to reduce androgen levels and improve prostate cancer symptoms. Conversely, those who consume high levels of dietary fats, polycyclic aromatic hydrocarbons (from cooking red meats), or calcium may be at an increased risk of developing advanced prostate cancer..|PSA levels in LNCaP tumor xenografts caring mice (25 mice. 9–16 weeks old, weight 16–28 g) It was also notable that serum average T levels of these mice was 0.83 ng ml−1 (range 0.32–2.3 ng ml−1), which mimics the serum T level in hypogonadal men (normal serum T level in adult men is between 2.4 and 9.5 ng ml−1- Mayo Clinic). Serum samples from 25 LNCaP tumor xenografts caring mice were tested for PSA levels. Five million cells in 200 ml serum-free medium were inoculated subcutaneously to each mouse (5–7 weeks old) and tumor development was checked every 2 days. T and DHT levels in 10% FBS supplemented medium and serum free medium were also tested by Elisa (T-Rocky Mountain Diagnostic, AA E-1300. DHT-MyBiosource MBS366006). However, more recent studies have shown that around 15% of men with PSA levels below 4.0 ng ml−1 have PCa.1,2,3|Alternatively, the doctor may recommend a prostate biopsy without further testing. If the PSA level continues to rise—especially if it rises quickly—or if a lump is detected during a DRE, the doctor may recommend additional tests. If the PSA level is still elevated, the doctor may recommend continued observation with repeat PSA tests along with digital rectal exams (DREs) to watch for any changes over time. People are generally recommended to wait until any conditions that can change PSA level resolve before they have testing and to avoid activities that may raise the PSA level for 2 days before testing. Vigorous exercise (such as cycling) and ejaculation can also increase the PSA level transiently.|Cancer cases with localized tumors (T1 or T2), no spread (N0 and M0), Gleason grade group 1, and PSA less than 10 ng/mL are designated stage I. Prostate cancer is typically staged using the American Joint Committee on Cancer's (AJCC) three-component TNM system, with scores assigned for the extent of the tumor (T), spread to any lymph nodes (N), and the presence of metastases (M). The extent of cancer spread is assessed by MRI or PSMA scan – a positron emission tomography (PET) imaging technique where a radioactive label that binds the prostate protein prostate-specific membrane antigen is used to detect metastases distant from the prostate. The Gleason grading system is commonly used, where the pathologist assigns numbers ranging from 3 (most similar to healthy prostate tissue) to 5 (least similar) to different regions of the biopsied tissue. Next, tumor samples are graded based on how much the tumor tissue differs from normal prostate tissue; the more different the tumor appears, the faster the tumor is likely to grow. MRI results can help distinguish those who have potentially dangerous tumors from those who do not.|An animal study by Morgentaler and Traish showed that beyond a certain serum testosterone concentration, androgens have a limited ability to stimulate prostate cancer growth . Long-term cessation of the prostate's exposure to androgen appears to protect against the development of cancer, but no dose-response relationship between testosterone level and cancer risk has been established. Odds ratios with 95% confidence intervals (CIs) for PSA, PSAD, serum testosterone, and age were determined to predict prostate cancer risk. For possible correlation between serum testosterone, PSA, and prostate cancer, we included age, PSA density (PSAD), prostate volume, and Gleason score for patients with prostate cancer. To determine the relationship between testosterone, PSA, and prostate cancer risk in a high-risk group, we limited our study population to men with a PSA level of 10 ng/ml or higher. Isbarn et al's recent studies, however, show a result opposite that of Huggins and Hodges, implying that testosterone neither increases the risk of prostate cancer nor causes cancer recurrence in men who have been treated successfully for prostate cancer .|Testosterone plays a key role in the development of male reproductive tissues such as the testes and prostate gland . Hypogonadal and eugonadal men did not differ significantly in cancer detection rate (30.2% vs. 32.0%, respectively). All men were assessed by a transrectal ultrasound (TRUS)-guided biopsy of the prostate. The study population consisted of 120 men with a PSA level of 10 ng/ml or higher.|Prostate specific antigen is produced almost exclusively by prostate epithelial cells, which have AR. Furthermore, these cells ceased PSA production after consecutive serum-free medium changes in 4 days. The in vitro data demonstrated cultured LNCaP cells decreased PSA production after the cells were shifted to serum-free culture conditions. Cultured LNCaP cells (passages 20 to 50) were detached and separated by 0.25% trypsin-EDTA solution (Gibco, 25300) and washed by serum free medium. Twenty-four hours later, PSA levels in medium from each well were tested with PSA Elisa kit (MyBiosource, MBS494521). In order to better understand why a significant amount of men with low PSA levels have PCa, in this study, we aimed to investigate the relationship of T levels and PSA production in both in vitro and in vivo experiments. The production of PSA is responsive to androgens and testosterone (T) is the primary and main form of androgens.|It is often diagnosed when the prostate has enlarged to the point where urination becomes difficult. An enlarged prostate is called prostatomegaly, with benign prostatic hyperplasia (BPH) being the most common cause. More recently, a combination of trigger point and psychological therapy has proved effective for category III prostatitis as well. When inflamed, the prostate becomes enlarged and is tender when touched during digital rectal examination. Inflammation of the prostate can cause painful urination or ejaculation, groin pain, difficulty passing urine, or constitutional symptoms such as fever or tiredness. This has led to the area of the rectal wall adjacent to the prostate to be popularly referred to as the "male G-spot". It is possible for some men to achieve orgasm solely through stimulation of the prostate gland, such as via prostate massage or anal intercourse.}
Interestingly, 2 of the included studies examined the effect of testosterone replacement in men with type 2 diabetes mellitus and whereas one22 found that IM testosterone did not have an effect on insulin resistance or dyslipidemia, the other20 showed that transdermal replacement had a beneficial effect on insulin resistance and lipid levels. Only 3 studies provided data with respect to the development of prostate cancer (Table 2). Forest plot comparing the number of patients with elevated PSA level after treatment between patients receiving testosterone treatment via transdermal, oral (PO) and intramuscular (IM) routes versus control treatments. Forest plot comparing PSA level change between patients receiving testosterone treatment via transdermal, oral (PO) and intramuscular (IM) routes versus control treatments. Nine of the 15 studies provided complete data regarding PSA levels before and after treatment (Figure 2). For the difference of PSA levels between before and after treatment, the difference in means with 95% confidence interval (CI) between testosterone and control treatments was calculated. The systematic review and meta-analysis aimed to determine the effect of testosterone replacement therapy on PSA levels.
This was improved upon by Patrick C. Walsh's 1983 description of a retropubic prostatectomy approach that avoided damage to the nerves near the prostate, preserving erectile function. In 1945, Terence Millin described a retropubic prostatectomy approach, which provided easier access to pelvic lymph nodes to assist in staging the extent of disease, and was easier for surgeons to learn. In 1931 a new surgical method, transurethral resection of the prostate, became available, replacing perineal prostatectomy for symptomatic relief of obstruction. Perineal prostatectomy was first performed in 1904 by Hugh H. Young at Johns Hopkins Hospital. Around the turn of the 19th century, prostate surgery to relieve urinary obstruction became more common, allowing surgeons and pathologists to examine the removed prostate tissue.
TRT doesn’t fix or cure the underlying cause of low testosterone. This can help improve the symptoms of low testosterone, like low libido and lack of energy. As of 2025, it’s not yet approved for males who naturally experience a decline in testosterone as they age. For example, chemotherapy or radiation therapy can damage one of these organs. Together, you and your healthcare provider will decide if TRT is right for you.
https://www.ikaros.asia/shannatolmer7